A relação dos efeitos colaterais do medicamento semaglutida para a perda de peso em pacientes obesos ou com sobrepesos em diabetes mellitus tipo 2

Abstract

INTRODUCTION: Obesity is a pandemic of the 21st century, it is a chronic disease that affects quality of life and is hypertension and diabetes. The search for therapeutic treatments, including medications, has increased, leading to “off-label” use. Ozempic, whose active ingredient is Semaglutide, has been used weight loss, although originally intended for the treatment of Type 2 Diabetes Mellitus. OBJECTIVES: This study aims to understand the relationship between the drug Semaglutide and weight loss in obese patients and overweight without type 2 Diabetes Mellitus, exploring its mechanism of action and side effects. METHODOLOGY: The study consists of a descriptive and qualitative narrative review. A bibliographic survey was carried out in several databases, selecting 13 articles that met the inclusion and exclusion criteria. RESULTS: Articles were selected that highlight the effectiveness of Semaglutide in weight loss, highlighting benefits such as reduced cardiovascular risks and glycemic control. However, there are warnings about significant risks such as medication shortages and lack of specialized guidance. CONCLUSION or FINAL CONSIDERATIONS: Highlights the potential benefits of Semaglutide in weight loss, but emphasizes the importance of an integrated approach, including lifestyle changes. The need for further studies and understanding of Semaglutide’s action medications is highlighted. The work contributes to the understanding of the use of Semaglutide as a therapeutic option for obesity, offering insights for health professionals and researchers.